Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Fairfax, BP, Pratap, S, Roberts, ISD, Collier, J, Kaplan, R, Meade, AM, Ritchie, AW, Eisen, T, Macaulay, VM, Protheroe, A
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575366/
https://ncbi.nlm.nih.gov/pubmed/23231599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-590
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki